AstraZeneca's trial flopped. The stock dropped. Analysts now question whether the company's premium valuation still makes sense given that sometimes experiments fail.
This counts as news because investors apparently forgot that drug trials can produce negative results. They priced the stock like every molecule in the pipeline would turn into a blockbuster. One didn't. The premium wobbled.
The company commanded one of the richest valuations among large European pharma firms on the assumption it consistently delivers results. That assumption lasted until it didn't deliver a result. Shocking stuff.
Retail traders bought shares based on vibes and a chart that went up for a while. They convinced themselves AstraZeneca scientists possessed some magical ability to turn every compound into billions of dollars. The scientists are smart. They are not wizards. Drugs fail in trials. This happens roughly all the f*cking time in pharma.
The bigger question, according to the headline, is whether the pipeline premium has become more vulnerable. The answer is yes. It became vulnerable the moment one trial failed. That is how premiums work. They exist until evidence suggests they shouldn't.
Analysts will now spend weeks publishing reports that say AstraZeneca might not be worth as much if its drugs don't work. This will be presented as insight. It is just basic arithmetic with a cover page.
The real comedy here is that the valuation premium existed because AstraZeneca consistently delivered results until the exact moment it stopped consistently delivering results. Investors paid extra for consistency and got inconsistency instead. They could have just bought an index fund and avoided learning this lesson about the word "consistently."
Photo by Mika Baumeister on Unsplash
Leave a Comment